Home Cart Sign in  
Chemical Structure| 881202-45-5 Chemical Structure| 881202-45-5
Chemical Structure| 881202-45-5

Serdemetan

CAS No.: 881202-45-5

Serdemetan acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis inp53 wild-type cells, and inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.

Synonyms: JNJ-26854165

4.5 *For Research Use Only !

Cat. No.: A603239 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
25mg łËÇʶÊÊ Inquiry Inquiry
50mg ł§ÿò¶ÊÊ Inquiry Inquiry
100mg łòÊÿ¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 25mg

    łËÇʶÊÊ

  • 50mg

    ł§ÿò¶ÊÊ

  • 100mg

    łòÊÿ¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Serdemetan

CAS No. :881202-45-5
Formula : C21H20N4
M.W : 328.41
SMILES Code : C(CC1=CNC2=C1C=CC=C2)NC1=CC=C(NC2=CC=NC=C2)C=C1
Synonyms :
JNJ-26854165
MDL No. :MFCD16620518
InChI Key :CEGSUKYESLWKJP-UHFFFAOYSA-N
Pubchem ID :11609586

Safety of Serdemetan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Serdemetan

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • E3 Ligase

In Vitro:

Cell Line
Concentration Treated Time Description Reference
293T cells 5 µM 24 hours Observed accumulation of cholesterol within endosomes PMC3876782
U373 cells 10 μM 6 hours Detected p53 and p21 levels, found Serdemetan did not significantly induce p21 PMC3765416
SF767 cells 10 μM 6 hours Detected p53 and p21 levels, found Serdemetan did not significantly induce p21 PMC3765416
U87MG cells 30 μM 6 hours Detected p53 and Mdm2 levels, found Serdemetan increased p53 levels but did not robustly induce Mdm2 PMC3765416
MM cells 1.43-2.48 μM (IC50) 72 hours Evaluated proliferation inhibition, showing dose-dependent inhibition PMC3876782
MCL cells 0.25-3 μM (IC50) 72 hours Evaluated proliferation inhibition, showing dose-dependent inhibition PMC3876782
U87 cells 10 μM Detected VEGF promoter activity, found Serdemetan reduced VEGF levels PMC3765416

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00676910 Neoplasms PHASE1 COMPLETED 2025-02-10 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.04mL

0.61mL

0.30mL

15.22mL

3.04mL

1.52mL

30.45mL

6.09mL

3.04mL

References

 

Historical Records

Categories